Management of type 2 diabetes: new and future developments in treatment

Keyphrases

• Increasing Prevalence 100%
• Liver 100%
• Natural History 100%
• Type 2 Diabetes Mellitus (T2DM) 100%
• New Treatment Options 100%
• G Protein-coupled 100%
• 11β-hydroxysteroid Dehydrogenase 100%
• Once-weekly 100%
• Satiety 100%
• A1 Receptor 100%
• Glycemic Control 100%
• Receptor Agonist 100%
• Glucocorticoid-induced 100%
• Type 2 Diabetes Complications 100%
• Postprandial Insulin 100%
• Insulin Secretion 100%
• Bariatric Surgery 100%
• Metabolic Inhibitors 100%
• Hepatic Glucose Production 100%
• Insulin Action 100%
• Glucagon 100%
• Dipeptidyl peptidase-4 (DPP-4) 100%
• Glucagon-like 100%
• Incretin Hormones 100%
• Insulin Release 100%
• Glucokinase Activator 100%
• Glucagon Receptor Antagonist 100%
• Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i) 100%
• Fatty Acid Receptor 100%
• Renal Glucose 100%

Medicine and Dentistry

• Maturity Onset Diabetes of the Young 100%
• Receptor 50%
• Prevalence 50%
• Glucocorticoid 50%
• 11beta Hydroxysteroid Dehydrogenase 1 50%
• Fatty Acid 50%
• Glycemic 50%
• Guanine Nucleotide Binding Protein 50%
• Bariatric Surgery 50%
• Glucagon 50%
• Insulin Release 50%
• Satiety 50%
• Incretin 50%
• Glucokinase 50%
• Glucagon Like Peptide 1 Receptor 50%
• Dipeptidyl Peptidase IV 50%
• Glucagon Receptor Antagonist 50%
• Sodium Glucose Cotransporter 2 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Insulin Dependent Diabetes Mellitus 100%
• Prevalence 50%
• Guanine Nucleotide Binding Protein 50%
• 11beta Hydroxysteroid Dehydrogenase 1 50%
• Glucocorticoid 50%
• Glucokinase 50%
• Elimination 50%
• Receptor Agonist 50%
• Fatty Acid 50%
• Incretin 50%
• Dipeptidyl Peptidase IV 50%
• Glucagon 50%
• Sodium Glucose Cotransporter 2 50%
• Glucagon Receptor Antagonist 50%
• Glucagon-Like Peptide 1 Receptor 50%